Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT4WU3
|
|||
| Drug Name |
TTC-352
|
|||
| Synonyms |
Sherpa TTC-352; UNII-65ILH3Y0MI; 65ILH3Y0MI; CHEMBL3763743; 1607819-68-0; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol; SCHEMBL15658409; BDBM50145856; J3.603.123I; 2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol; Selective human estrogen-receptor alpha partial agonist TTC-352; Benzo(b)thiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-; V9J
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Metastatic melanoma [ICD-11: 2E2Z; ICD-10: C76-C80] | Phase 1 | [1] | |
| Company |
TTC Oncology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H13FO3S
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C2=C(SC3=C2C=CC(=C3)O)OC4=CC=C(C=C4)O)F
|
|||
| InChI |
1S/C20H13FO3S/c21-13-3-1-12(2-4-13)19-17-10-7-15(23)11-18(17)25-20(19)24-16-8-5-14(22)6-9-16/h1-11,22-23H
|
|||
| InChIKey |
UDBMVVLTKJMPCJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1607819-68-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03201913) Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of TTC Oncology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.